Enhanced Implantable Cardioverter-Defibrillator (ICD) System with Substernal Pacing Lead

The present invention relates to an improved implantable cardioverter-defibrillator (ICD) system with a substernal pacing lead, designed to reduce cardiac tissue damage during defibrillation and provide more efficient and effective cardiac defibrillation.

The original patent disclosed an ICD system with a substernal pacing lead, which, although effective, had limitations in terms of cardiac tissue damage during defibrillation. The present invention addresses these limitations by introducing novel features that optimize the defibrillation pulse and reduce cardiac tissue damage.

The enhanced ICD system comprises an ICD, a substernal pacing lead, and a cardiac tissue protection module. The substernal pacing lead is designed to reduce cardiac tissue damage during defibrillation, and the cardiac tissue protection module adjusts the defibrillation pulse width and amplitude based on the patient's cardiac tissue characteristics. The system can also include a real-time cardiac tissue monitoring module to detect cardiac tissue damage during defibrillation and adjust the defibrillation pulse accordingly. The inventive concept provides a more efficient and effective cardiac defibrillation system that reduces cardiac tissue damage.

The novel features of the present invention include the cardiac tissue protection module, the real-time cardiac tissue monitoring module, and the optimized defibrillation pulse. These features provide a non-obvious solution to the problem of cardiac tissue damage during defibrillation, and offer a significant improvement over the original patent.

Alternative embodiments of the inventive concept may include different configurations of the substernal pacing lead, such as varying the electrode design or the lead's geometry. Additionally, the cardiac tissue protection module and real-time cardiac tissue monitoring module could be implemented using different algorithms or sensing technologies.

The enhanced ICD system has significant commercial potential in the cardiac rhythm management market, particularly in the area of implantable cardioverter-defibrillators. The system's ability to reduce cardiac tissue damage during defibrillation makes it an attractive solution for patients at risk of cardiac arrhythmias.